Press release: STADA extends European oncology offering by launching lenalidomide
STADA extends European oncology offering by launching lenalidomide
- STADA introduces lenalidomide generic alternative to Revlimid in more than a dozen European countries
- Market entry with the multiple myeloma treatment ahead of patent expiry adds to a comprehensive offering for oncologists and their patients, such as a convenient ready-to-use formulation of bortezomib
- STADA CEO Peter Goldschmidt: “Introducing lenalidomide in major European markets is testament to STADA’s vision to be a go-to-partner, offering a wide range of cancer treatments.”
Bad Vilbel, 18 February 2022 – STADA is broadening its oncology portfolio by introducing a generic alternative to Revlimid (lenalidomide) capsules in more than a dozen European countries from 18 February. Under the terms of a patent-litigation settlement, STADA is now able to offer the multiple myeloma and lymphoma treatment to oncologists and their patients in countries including France, Germany, Italy and Spain.
Patients in Belgium, the Czech Republic, Ireland, the Netherlands, Poland and Portugal are also set to benefit from generic competition to Revlimid, as are patients in Denmark, Finland and Sweden.
Revlimid is one of the world’s best-selling medicines. The originator, Bristol Myers Squibb, reported global Revlimid sales in 2021 of US$12.8 billion, including US$4.1 billion outside of the US.
Approximately 40,000 people in Europe were diagnosed with myeloma in 2015, making it the second most common blood cancer after non-Hodgkin lymphoma .
“Introducing lenalidomide in major European markets is testament to STADA’s vision to be a go-to-partner, offering a wide range of cancer treatments,” commented STADA CEO Peter Goldschmidt. “Increasing competition in the oncology sector has the potential to drive down prices and contribute to equity of access to cancer care.”
Available in seven capsule strengths, ranging from 2.5mg to 25mg, to provide flexibility of dosing, Lenalidomide STADA strengthens the group’s existing A-to-Z offering for oncologists and their patients. This ranges from anastrozole, azacytidine and a convenient ready-to-use formulation of bortezomib through to vinblastine and zoledronic acid. STADA also markets a range of biologic medicines for cancer-related uses, including bevacizumab, epoetin zeta and pegfilgrastim.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 713.3 million. As of 31 December 2020, STADA employed 12,301 people worldwide.
 Incidence of myeloma – Myeloma Patients Europe (mpeurope.org)
Additional information for journalists:
STADA Arzneimittel AG - Media Relations Stadastrasse 2-18 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165 Fax: +49 (0) 6101 603-215 E-Mail: email@example.com
Or visit us on the Internet at www.stada.com/press Follow @STADAGroup on LinkedIn
Additional information for capital market participants:
STADA Arzneimittel AG - Investor & Creditor Relations Stadastrasse 2-18 61118 Bad Vilbel – Germany Phone: +49 (0) 6101 603-4689 Fax: +49 (0) 6101 603-215 E-mail: firstname.lastname@example.org
Or visit us on the Internet at www.stada.com/investor-relations